• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

哌拉西林联合用药的酶学方面

[Enzymologic aspect of piperacillin combinations].

作者信息

Labia R, Morand A, Verchere-Beaur C, Amrani R, Beklahia C

出版信息

Presse Med. 1986 Dec 20;15(46):2303-8.

PMID:2949272
Abstract

Like all penicillins, piperacillin exhibits some susceptibility to beta-lactamases of the penicillinase type, including those produced by Staphylococcus aureus and the TEM, OXA and CARB enzymes isolated from Gram-negative bacilli. Piperacillin is very slightly hydrolyzed by cephalosporinases, which makes it similar to 3rd generation cephalosporins. When tested with Enterobacter cloacae GN 5797 and Pseudomonas aeruginosa NTC 8303, two strains which produce inducible cephalosporinases, piperacillin had moderate inductive activity compared to cefoxitin, a potent inducer. Induction was very low with Enterobacter, but the drug was slightly more sensitive to Pseudomonas. Inhibition of this type of beta-lactamase synthesis was very strong when piperacillin was combined with amikacin and weaker when it was combined with pefloxacin. The piperacillin-amikacin combination prevented the development of piperacillin-resistant mutants of Enterobacter and Pseudomonas and, probably, of all Gram-negative bacilli. In our tests, the piperacillin-pefloxacin combination was of interest only against Enterobacter, and probably against all enterobacteria, since Pseudomonas mutants that resist pefloxacin are fairly easily obtained in vitro.

摘要

与所有青霉素一样,哌拉西林对青霉素酶类型的β-内酰胺酶表现出一定的敏感性,包括金黄色葡萄球菌产生的酶以及从革兰氏阴性杆菌中分离出的TEM、OXA和CARB酶。哌拉西林被头孢菌素酶水解的程度非常轻微,这使其与第三代头孢菌素相似。在用阴沟肠杆菌GN 5797和铜绿假单胞菌NTC 8303这两种可产生诱导型头孢菌素酶的菌株进行测试时,与强效诱导剂头孢西丁相比,哌拉西林具有中等诱导活性。在阴沟肠杆菌中诱导作用非常低,但该药物对铜绿假单胞菌的敏感性略高。当哌拉西林与阿米卡星联合使用时,对这种类型的β-内酰胺酶合成的抑制作用非常强,而与培氟沙星联合使用时则较弱。哌拉西林-阿米卡星组合可防止阴沟肠杆菌和铜绿假单胞菌以及可能所有革兰氏阴性杆菌的哌拉西林耐药突变体的产生。在我们的测试中,哌拉西林-培氟沙星组合仅对阴沟肠杆菌有作用,可能对所有肠杆菌都有作用,因为在体外相当容易获得对培氟沙星耐药的铜绿假单胞菌突变体。

相似文献

1
[Enzymologic aspect of piperacillin combinations].哌拉西林联合用药的酶学方面
Presse Med. 1986 Dec 20;15(46):2303-8.
2
Interaction between piperacillin and pefloxacin or amikacin on the selection of resistant mutants of Pseudomonas aeruginosa.哌拉西林与培氟沙星或阿米卡星对铜绿假单胞菌耐药突变体选择的相互作用。
J Antimicrob Chemother. 1988 Nov;22(5):651-7. doi: 10.1093/jac/22.5.651.
3
Bactericidal activity and killing rate of serum in volunteers receiving pefloxacin alone or in combination with ceftazidime, piperacillin or mezlocillin against Pseudomonas aeruginosa.
J Antimicrob Chemother. 1988 Jan;21(1):49-55. doi: 10.1093/jac/21.1.49.
4
In-vitro activity of pefloxacin compared to other antibiotics.培氟沙星与其他抗生素相比的体外活性。
J Antimicrob Chemother. 1986 Apr;17 Suppl B:19-28. doi: 10.1093/jac/17.suppl_b.19.
5
[Piperacillin-amikacin combinations: killing curves].[哌拉西林-阿米卡星联合用药:杀菌曲线]
Pathol Biol (Paris). 1990 Sep;38(7):682-9.
6
Importance of beta-lactamase induction.β-内酰胺酶诱导的重要性。
Eur J Clin Microbiol Infect Dis. 1993;12 Suppl 1:S19-26. doi: 10.1007/BF02389873.
7
Emergence of resistance after therapy with antibiotics used alone or combined in a murine model.
J Antimicrob Chemother. 1986 Mar;17 Suppl A:11-8. doi: 10.1093/jac/17.suppl_a.11.
8
Pseudomonas aeruginosa beta-lactamase as a defence against azlocillin, mezlocillin and piperacillin.铜绿假单胞菌β-内酰胺酶对阿洛西林、美洛西林和哌拉西林的防御作用。
J Antimicrob Chemother. 1984 Sep;14(3):221-9. doi: 10.1093/jac/14.3.221.
9
Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).新型喹诺酮类药物氟罗沙星(RO 23 - 6240)的体外活性比较
Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):63-6. doi: 10.1007/BF01962177.
10
Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.产超广谱β-内酰胺酶(ESBL)和Amp-Cβ-内酰胺酶的情况以及复杂尿路感染对新型抗菌药物的敏感性
Indian J Med Res. 2008 Jan;127(1):85-8.